Mizuho Securities USA appoints new head of biotech research

Mizuho Securities USA (MSUSA), the U.S. investment banking subsidiary of Mizuho Financial Group, has appointed Salim Syed as Managing Director and Head of Biotechnology Research. He joins the firm with more than twelve years on Wall Street and will report to Sheryl Skolnick, Ph.D., Managing Director and Head of Equity Research.

“We continue to build a premier U.S. equity research franchise that is a leader in actionable value-added investment idea generation and analysis,” said John Koudounis, MSUSA President & CEO. “Salim comes to us with great depth of expertise in the biotech sector and will be a great addition to the firm.”

Syed joins MSUSA from Evercore ISI, where he spent the previous six years as Director, Biotech/Pharma Equity Research. Prior to Evercore, he was an investment banker working on M&A and capital market transactions at Morgan Stanley, where he began his career. Syed earned a Bachelor of Business Administration degree at the University of Michigan.

“The expansion of research coverage with such an experienced and highly-regarded analyst as Salim further demonstrates our commitment to providing clients with a seasoned team of professionals and a first-rate research product,” said Matt DeSalvo, Executive Managing Director and Head of MSUSA’s Equity Division.

JefferiesAnd the Best Place to Work in the global financial markets 2017 is...

Register for Financial Markets News Alerts